Latest News and Press Releases

ALLSCHWIL/BASEL, Switzerland, July 20, 2006 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced its financial results for the first six months of 2006. With total net revenue for H1 2006 of CHF...

Co-development for Actelion's Selective S1P1 Receptor Agonist in Multiple Indications With Co-promotion and Profit Share -- Actelion to Receive Upfront Payment of US$75 Million -- ...

ALLSCHWIL, Switzerland, July 6, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today that the renin alliance with Merck & Co., Inc. (NYSE:MRK) has achieved its third...

ALLSCHWIL, Switzerland, June 19, 2006 (PRIMEZONE) -- Actelion Ltd. (Other OTC:ALIOF) (SWX:ATLN) announced today that preliminary analysis of the dose-finding study CONSCIOUS-1 (Clazosentan to Overcome...

SAN DIEGO, May 23, 2006 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today that data presented from the BUILD program (Bosentan Use in Interstitial Lung Disease) at the American...

ALLSCHWIL and BASEL, Switzerland, April 20, 2006 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced its financial results for the first quarter of 2006. With total net revenue of CHF 210.6 million...

ALLSCHWIL and BASEL, Switzerland, April 10, 2006 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd. (Other OTC:ALIOF) (SWX:ATLN) shareholders approved all resolutions. Shareholders...

-- Total net revenue up 41% to CHF 663.6 million -- Tracleer(r) sales up 41 % to CHF 633.2 million -- Operating income up 78% to CHF 152.3 million -- Net income of CHF 125.5 million --...

ALLSCHWIL, Switzerland, Nov. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced that in the BUILD program with bosentan (Tracleer(R)) in patients suffering from either...

ALLSCHWIL, Switzerland and BRUSSELS, Belgium, Nov. 17, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) and UCB (Euronext: UCB, UCBBt.RR, UCB BB) today announced that the two companies...